Breaking News Instant updates and real-time market news.

AZSEY

Allianz

$0.00

(0.00%)

, CCL

Carnival

$65.47

0.29 (0.44%)

04:55
05/17/18
05/17
04:55
05/17/18
04:55

Verint systems to hold a customer conference

Engage: Global Customer Conference will be held in Dallas, Texas on May 14-17.

AZSEY

Allianz

$0.00

(0.00%)

CCL

Carnival

$65.47

0.29 (0.44%)

C

Citi

$71.93

-0.73 (-1.00%)

NRG

NRG Energy

$33.74

-0.01 (-0.03%)

SHLD

Sears

$3.81

0.32 (9.17%)

XRX

Xerox

$28.55

0.04 (0.14%)

VRNT

Verint

$41.75

(0.00%)

  • 30

    May

  • 06

    Jun

  • 21

    Jun

AZSEY Allianz
$0.00

(0.00%)

02/08/18
JEFF
02/08/18
DOWNGRADE
JEFF
Hold
Allianz downgraded to Hold from Buy at Jefferies
Jefferies analyst Philip Kett yesterday downgraded Allianz to Hold.
02/08/18
DBAB
02/08/18
UPGRADE
Target $32
DBAB
Hold
XL Group upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Joshua Shanker upgraded XL (XL) Group to Hold citing the threat of an acquisition after Bloomberg reported that the company has attracted interest from rivals including Allianz (AZSEY). The analyst keeps a $32 price target for the shares. He does not believe an acquisition of XL makes sense for Allianz, however.
12/11/17
LEHM
12/11/17
UPGRADE
LEHM
Equal Weight
Allianz upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Claudia Gaspari upgraded Allianz to Equal Weight with a price target of EUR 204.
03/29/18
JPMS
03/29/18
DOWNGRADE
JPMS
Neutral
Allianz downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Huttner downgraded Allianz to Neutral and lowered his price target for the shares to EUR 217 from EUR 240. The analyst cites relative valuation for the downgrade and believes capital management is a key driver for continued outperformance.
CCL Carnival
$65.47

0.29 (0.44%)

03/23/18
LEHM
03/23/18
UPGRADE
LEHM
Overweight
Carnival upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Felicia Hendrix upgraded Carnival to Overweight with a $77 price target following the company's Q1 results. The analyst views the stock's valuation as attractive relative to peers and believes Carnival's fundamentals are strong.
01/09/18
FBCO
01/09/18
UPGRADE
Target $78.1
FBCO
Outperform
Carnival upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Tim Ramskill upgraded Carnival to Outperform and raised his price target for the shares to $78.10 from $72.40. The analyst is no longer cautious on the stock following the 33% underperformance of the cruise sector relative to lodging since September. He highlights the "resilience" of Carnival's bookings and says its "earnings and yield momentum dynamics are intact."
04/13/18
WEDB
04/13/18
NO CHANGE
Target $145
WEDB
Outperform
Caribbean cruise capacity concerns real, but overstated, says Wedbush
Wedbush analyst James Hardiman told investors in a research note that while he believes the risk surrounding capacity concerns and the general health of the Caribbean market is real, it is unlikely to threaten cruise companies' abilities to achieve previously communicated guidance. While March pricing for Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH) was flat to down, Hardiman noted that it did show sequential improvement on both a year-over-year and two-year average basis, adding that Carnival (CCL) saw positive pricing growth, though the growth has decelerated sequentially. Hardiman continues to rate Royal Caribbean and Norwegian Outperform and Carnival Neutral, with price targets of $145, $65, and $71, respectively, and says Norwegian remains on the firm's Best Ideas List, as it has the least amount of exposure to the Caribbean market and major exposure to the "hot" European market.
04/11/18
STFL
04/11/18
NO CHANGE
Target $81
STFL
Buy
Carnival should be bought on weakness, says Stifel
Stifel notes that Carnival announced a 11% increase in its quarterly dividend to 50c per share and initiated a new $1B share repurchase authorization. Although Caribbean pricing concerns brought about by recent industry channel checks and pricing surveys have placed downward pressure on shares across the cruise operator group, the firm encourages investors to look beyond the noise of one particular market and focus on what very much remain strong underlying fundamentals supported by a truly global business. Stifel reiterates a Buy rating and $81 price target on Carnival shares and encourages investors to take advantage of what it views as an irrational pullback to add to or initiate positions in the name.
C Citi
$71.93

-0.73 (-1.00%)

04/11/18
04/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Citi (C) upgraded to Buy from Hold at HSBC with analyst Alevizos Alevizakos saying he sees improved profitability in the near-term, driven by U.S. dollar depreciation and tax reform, re-rating the shares higher. 2. BHP Billiton (BHP) upgraded to Buy from Hold at Deutsche Bank with analyst Liam Fitzpatrick saying the shares offer compelling value at current levels. 3. Mattel (MAT) upgraded to Hold from Underperform at Jefferies with analyst Stephanie Wissink saying the company's near-term risks are largely known and priced into the shares. 4. AeroVironment (AVAV) upgraded to Buy from Hold at Stifel with analyst Joseph DeNardi saying he sees the company benefiting from tailwinds including an improving defense budget environment, a heightened global threat environment, and "as strong a pipeline of opportunities" as he has seen in ten years. 5. Helmerich & Payne (HP) upgraded to Market Perform from Underperform at Wells Fargo with analyst Judson Bailey citing strength in the land rig market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/18
BMOC
04/17/18
NO CHANGE
Target $34
BMOC
Market Perform
Bank of America is the best of the 'big four' U.S. banks, says BMO Capital
BMO Capital analyst James Fotheringham kept his Market Perform rating and $34 price target on Bank of America (BAC) after its in-line Q1 earnings but raised his FY18 EPS view to $2.62 from $2.59 and FY19 view to $3.18 from $3.12. Fotheringham says than in contrast, he lowered earnings forecasts for JPMorgan (JPM), Wells Fargo (WFC), and Citigroup (C) because of higher costs and lower revenues, but Bank of America's better than expected net interest income rise justifies his view of the bank as the "best of the bunch". The analyst also notes the bank's more favorable valuation trading at a below-average two-year-forward P/E multiple despite his forecast of double the core earnings growth rate of Bank of America's peers.
04/11/18
HSBC
04/11/18
UPGRADE
Target $85
HSBC
Buy
Citi upgraded to Buy from Hold at HSBC
HSBC analyst Alevizos Alevizakos upgraded Citi to Buy and raised his price target for the shares to $85 from $82. The analyst sees improved profitability in the near-term, driven by U.S. dollar depreciation and tax reform, re-rating the shares higher. He believes the market is not fully appreciating Citi's leading credit card franchise and its growth prospects in Mexico.
04/05/18
04/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Overweight from Equal Weight at Barclays with analyst Geoffrey Meacham saying he believes the company will continue to take share in first-line lung cancer, driven by positive KN-189 and KN-042 data. 2. Acuity Brands (AYI) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha saying he believes the stock is finally trading at a "reasonable valuation based on reasonable expectations." 3. AMD (AMD) upgraded to Buy from Hold at Stifel with analyst Kevin Cassidy citing valuation and the company's margin expansion potential. 4. Tiffany (TIF) upgraded to Buy from Hold at Loop Capital with analyst Laura Champine saying her initial meeting with the company's new CEO Alessandro Bogliogo added to her confidence. 5. Citi (C) and Wells Fargo (WFC) were upgraded to Buy from Neutral at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NRG NRG Energy
$33.74

-0.01 (-0.03%)

07/13/17
LEHM
07/13/17
NO CHANGE
Target $27
LEHM
Overweight
NRG Energy price target raised to $27 from $20 at Barclays
Barclays analyst Daniel Ford raised his price target for NRG Energy to $27 saying the company's transformation plan is "significantly accretive." NRG's plan to sell between a 50%-100% stake in NRG Yield and Renewables, plus 6GWs of conventional generation can achieve management's projected $2.0B-$4.5B in cash proceeds and reduction of $8.7B in debt, Ford tells investors in a research note. His upside case has $11 per share of valuation accretion to $38 per share. The analyst reiterates an Overweight rating on the shares.
02/23/18
UBSW
02/23/18
INITIATION
Target $21
UBSW
Neutral
Vistra Energy initiated with a Neutral at UBS
UBS analyst Daniel Ford started Vistra Energy (VST) with a Neutral rating and $21 price target. The analyst views the shares as fairly valued without the Dynegy (DYN) deal and prefers shares of NRG Energy (NRG).
02/23/18
UBSW
02/23/18
INITIATION
Target $33
UBSW
Buy
NRG Energy initiated with a Buy at UBS
UBS analyst Daniel Ford started NRG Energy with a Buy rating and $33 price target. The analyst sees the stock moving to his price target as asset sales close and return of capital plans are revealed at the analyst day on March 27.
08/16/17
DBAB
08/16/17
NO CHANGE
Target $38
DBAB
Buy
NRG Energy shares have 50% more upside, says Deutsche Bank
Deutsche Bank analyst Abe Azar raised his price target for NRG Energy shares to $38 from $27 to reflect the company's planned transformation. Even with the rally year-to-date, NRG is still trading at an "unwarranted significant discount to peers," Azar tells investors in a research note titled "Baby, we were born to run." The analyst believes the stock has an additional 50% upside and reiterates a Buy rating on the name. Asset sales throughout the year and an investor day early next year set up a "favorable catalyst calendar and should lead to the stock to re-rate higher," Azar writes.
SHLD Sears
$3.81

0.32 (9.17%)

04/19/18
MSCO
04/19/18
NO CHANGE
Target $1550
MSCO
Overweight
Amazon gaining apparel market share in U.S., says Morgan Stanley
Morgan Stanley analyst Brian Nowak said his analysis shows that Amazon (AMZN) gained 1.5% of U.S. apparel market share in 2017, largely at the expense of department stores. He estimates Amazon is the second largest U.S. apparel retailer, trailing only Walmart (WMT), and expects the e-commerce giant to take the number one spot in terms of U.S. apparel market share in 2018. Cumulatively, Nowak estimates Sears (SHLD), Macy's (M) and J.C. Penney (JCP) lost 0.8% share in 2017, with shareholdings remaining roughly flat for Target (TGT) and Kohl's (KSS). He maintains an Overweight rating and $1,550 price target on Amazon shares.
05/09/18
JEFF
05/09/18
NO CHANGE
Target $60
JEFF
Hold
Sears-Amazon tire partnership not a negative for Monro, says Jefferies
Jefferies analyst Bret Jordan kept his Hold rating and $60 price target on Monro (MNRO) after its stock price fell over 7.5% today to $52.70, saying Sears (SHLD) partnership with Amazon (AMZN) on tire installation and services is a not "transformational negative". Jordan notes that the greater transparency and price matching is not new, while Monro is "already an installer for other online sellers such as Tirerack and ATD's tirebuyer.com". The analyst adds that the agreement is not exclusive, leaving the "door open" for Monro to enter into a similar deal.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $100
JEFF
Buy
Bon-Ton Stores bankruptcy benefits Kohl's, says Jefferies
Jefferies analyst Randal Konik notes that Bon-Ton Stores filed bankruptcy protection and provided the locations of the about 50 units slated for closure. The analyst now estimates near-term closures from Macy's (M), Sears (SHLD), Kmart, and Bon-Ton (BONT) should add about 18c to Kohl's (KSS) EPS and a 1.5% comp lift. Moreover, Konik believes the materialization of Bon-Ton's closures could be a "cherry on top" to accelerating fundamentals at Kohl's this year. He reiterates a Buy rating and $100 price target on Kohl's shares.
01/16/18
LOOP
01/16/18
NO CHANGE
Target $80
LOOP
Buy
Best Buy price target raised to $80 from $72 at Loop Capital
Loop Capital analyst Anthony Chukumba raised his price target on Best Buy (BBY) to $80, noting a more optimistic outlook for the stock thanks to some recent developments. The analyst cites strong November-December U.S. retail sales reports, PC shipments rising in Q4 for the first time in six years, and some closures of stores by Sears Holdings (SHLD) and Wal-Mart's (WMT) Sam's Club. Chukumba keeps his Buy rating on Best Buy.
XRX Xerox
$28.55

0.04 (0.14%)

05/16/18
LOOP
05/16/18
NO CHANGE
Target $40
LOOP
Buy
Xerox price target lowered to $40 from $45 at Loop Capital
Loop Capital analyst Ananda Baruah lowered his price target on Xerox (XRX) to $40, citing the potential operating disruptions from the company's leadership "saga" and the firm position by Fujifilm (FUJIY) not to raise its bid price. The analyst says his new price is based on the stand-alone value of the company with no added potential deal related benefits. Baruah also keeps his Buy rating on Xerox, adding that there is a greater "appreciation" by the recently appointed CEO John Visentin to pass on more cost savings toward profitability.
05/14/18
05/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dean Foods (DF) downgraded to Sell from Hold at Deutsche Bank analyst Rob Dickerson saying he still sees four fundamental challenges facing the company: continued declines in U.S. dairy milk consumption, its low-margin structured business, increasing vertical category integration by retailers, and what he views as low odds of transformative acquisitions. 2. Owens Corning (OC) downgraded to Market Perform from Outperform at Wells Fargo with analyst Stephen East saying his outlook for Roofing and Composites has weakened and extremely weak year to date 2018 hail/storm activity is likely an incremental headwind to 2H18 Shingle Volumes while inflationary cost pressures are more intense than originally expected. 3. Xerox (XRX) downgraded to Neutral from Overweight at JPMorgan and to Hold from Buy at Cross Research. 4. Jeld-Wen (JELD) downgraded to Neutral from Buy at BofA/Merrill with analyst John Lovallo saying he believes the company will face challenges from the CEO search, Steves & Sons litigation, wood windows, and believes a margin recovery could take longer than expected. 5. Hostess Brands (TWNK) downgraded to Hold from Buy at Deutsche Bank with analyst Rob Dickerson saying he is less certain on the base business' potential margin and profitability progression over the next twelve months following the company's recent earnings report. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/18
JPMS
05/14/18
DOWNGRADE
Target $38
JPMS
Neutral
Xerox downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Paul Coster downgraded Xerox to Neutral from Overweight as he believes it is unlikely that the new board will find an alternative acquirer for Xerox in the next few months after the company terminated its planned merger with Fuji-Xerox. Meanwhile, he sees Xerox being at risk of losing key enterprise accounts and sees more risk, particularly for the JV with Fuji-Xerox. Coster keeps a $38 price target on Xerox shares.
05/14/18
CRSS
05/14/18
DOWNGRADE
CRSS
Hold
Xerox downgraded to Hold from Buy at Cross Research
VRNT Verint
$41.75

(0.00%)

08/07/17
GSCO
08/07/17
UPGRADE
Target $50
GSCO
Conviction Buy
Verint upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman analyst Gabriela Borges added Verint to the Conviction Buy List with a $50 price target saying he expects a continued recovery in the Security business to drive operating margins given the strong backlog and heightened geopolitical risk environment.
12/12/17
OPCO
12/12/17
NO CHANGE
Target $49
OPCO
Outperform
Weakness in Verint stock unwarranted, says Oppenheimer
Oppenheimer analyst Shaul Eyal reiterates an Outperform rating and $49 price target on Verint following recent and "unwarranted" weakness in the stock. The analyst believes investors may have been expecting more margin improvement than was implicit in guidance. Longer term, he sees potential margin improvement in Cyber Intelligence toward low-mid teens and believes Verint is effectively balancing growth and profitability.
03/29/18
RBCM
03/29/18
NO CHANGE
Target $50
RBCM
Outperform
Verint price target raised to $50 at RBC Capital after Q4 earnings beat
RBC Capital analyst Dan Bergstrom raised his price target on Verint to $50 from $48, saying the company's Q4 earnings beat showed "improved consistency from each segment and better positioning". Bergstrom adds that the company's FY19 outlook for margin expansion was a positive surprise that well be "well received" by investors, noting that it also appears to be sustainable. The analyst keeps his Outperform rating on Verint and believes the company should outperform its peers amid growth in the unstructured data analytics and security segments, further adding that valuation on the stock looks "reasonable".

TODAY'S FREE FLY STORIES

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/20/18
05/20
04:55
05/20/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

CBS

CBS

$51.75

0.14 (0.27%)

, VIA

Viacom

$33.80

-0.75 (-2.17%)

13:23
05/19/18
05/19
13:23
05/19/18
13:23
Periodicals
CBS looks like a bargain, Barron's says »

In a follow-up story,…

CBS

CBS

$51.75

0.14 (0.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

, PEP

PepsiCo

$97.51

-0.45 (-0.46%)

13:10
05/19/18
05/19
13:10
05/19/18
13:10
Periodicals
Coca-Cola, PepsiCo look like bargains, Barron's says »

Investors have punished…

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$35.40

1.14 (3.33%)

10:32
05/19/18
05/19
10:32
05/19/18
10:32
Periodicals
Roku relevance worth taking note of, Barron's says »

Roku now is mostly a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

LOW

Lowe's

$86.31

0.85 (0.99%)

10:19
05/19/18
05/19
10:19
05/19/18
10:19
Periodicals
Lowe's turnaround what matters for long-term investors, Barron's says »

With Lowe's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AAPL

Apple

$186.31

-0.69 (-0.37%)

, ZTCOY

ZTE Corp.

$0.00

(0.00%)

08:41
05/19/18
05/19
08:41
05/19/18
08:41
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$186.31

-0.69 (-0.37%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

ACIA

Acacia Communications

$32.97

0.45 (1.38%)

OCLR

Oclaro

$8.88

-0.015 (-0.17%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GM

General Motors

$37.80

-0.51 (-1.33%)

F

Ford

$11.33

-0.12 (-1.05%)

FCAU

Fiat Chrysler

$21.86

-0.31 (-1.40%)

HMC

Honda

$32.98

-0.11 (-0.33%)

TM

Toyota

$136.04

-0.54 (-0.40%)

NSANY

Nissan

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VRX

Valeant

$22.15

0.12 (0.54%)

PFE

Pfizer

$35.64

-0.07 (-0.20%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

INSY

Insys Therapeutics

$6.95

-0.37 (-5.05%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

BAYRY

Bayer

$0.00

(0.00%)

GILD

Gilead

$68.01

0.41 (0.61%)

BMRN

BioMarin

$88.95

0.51 (0.58%)

MNK

Mallinckrodt

$15.70

-0.37 (-2.30%)

SHPG

Shire

$169.62

-2.18 (-1.27%)

MRK

Merck

$59.13

0.06 (0.10%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

TEVA

Teva

$21.23

0.12 (0.57%)

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

ACOR

Acorda Therapeutics

$23.65

-0.45 (-1.87%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

NVS

Novartis

$77.08

-0.07 (-0.09%)

RHHBY

Roche

$0.00

(0.00%)

GALE

Galena

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 24

    May

  • 25

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 22

    Aug

  • 27

    Aug

  • 07

    Sep

  • 10

    Sep

  • 12

    Sep

  • 05

    Oct

  • 23

    Oct

  • 13

    Nov

  • 20

    Dec

  • 21

    Dec

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/19/18
05/19
04:55
05/19/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

18:46
05/18/18
05/18
18:46
05/18/18
18:46
Hot Stocks
Solid Biosciences announces new preclinical data for SGT-001 »

Solid Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

18:04
05/18/18
05/18
18:04
05/18/18
18:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.4K…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

FXE

Euro Currency Trust

$113.01

-0.28 (-0.25%)

FXC

CurrencyShares Canadian Dollar Trust

$76.61

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$114.04

0.11 (0.10%)

18:02
05/18/18
05/18
18:02
05/18/18
18:02
Hot Stocks
Celanese raises prices for emulsion polymers and acetyls »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

JBHT

J.B. Hunt

$126.85

1.06 (0.84%)

18:01
05/18/18
05/18
18:01
05/18/18
18:01
Hot Stocks
J.B. Hunt director Garrison sells 100,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

17:56
05/18/18
05/18
17:56
05/18/18
17:56
Hot Stocks
AstraZeneca confirms FDA approval of Lokelma »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

XLE

Energy Select Sector SPDR

$78.11

-0.62 (-0.79%)

, XLU

Utilities SPDR

$48.97

-0.02 (-0.04%)

17:48
05/18/18
05/18
17:48
05/18/18
17:48
General news
Week ending ETF Scorecard: Energy rallies while Utilities and Real Estate slide »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$78.11

-0.62 (-0.79%)

XLU

Utilities SPDR

$48.97

-0.02 (-0.04%)

IYR

DJ US Real Estate Index Fund

$75.47

0.15 (0.20%)

XLP

Consumer Staples Sector SPDR

$49.53

-0.33 (-0.66%)

XLY

Consumer Discretionary Sector SPDR

$104.87

-0.12 (-0.11%)

XLB

S&P Select Materials SPDR

$59.87

0.09 (0.15%)

XLF

Financial Select Sector

$27.95

-0.255 (-0.90%)

XLV

Health Care Select Sector SPDR

$83.23

0.24 (0.29%)

XLK

Technology Select Sector SPDR

$68.89

-0.28 (-0.40%)

XLI

Industrial Select Sector SPDR

$75.34

0.45 (0.60%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

SLV

iShares Silver Trust

$15.48

-0.005 (-0.03%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

UNG

United States Natural Gas Fund

$23.19

-0.085 (-0.37%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.38

-0.095 (-0.11%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.28

0.475 (0.42%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.21

0.98 (0.84%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.76

0.4 (0.40%)

SHY

iShares 1-3 Year Treasury Bond

$83.18

0.05 (0.06%)

IWD

iShares Russell 1000 Value

$122.33

-0.49 (-0.40%)

IWF

iShares Russell 1000 Growth

$141.58

-0.03 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHN

athenahealth

$150.09

0.64 (0.43%)

17:37
05/18/18
05/18
17:37
05/18/18
17:37
Hot Stocks
Janus Henderson reports 11.9% stake in athenahealth, urges for sale process »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 06

    Jun

YGYI

Youngevity International

$3.90

-0.08 (-2.01%)

17:33
05/18/18
05/18
17:33
05/18/18
17:33
Syndicate
Breaking Syndicate news story on Youngevity International »

Youngevity International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:32
05/18/18
05/18
17:32
05/18/18
17:32
Periodicals
Kudlow: ZTE needs to overhaul management to get U.S. reprieve, Bloomberg says »

White House National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PF

Pinnacle Foods

$63.23

-0.45 (-0.71%)

, CAG

Conagra Brands

$37.43

-0.28 (-0.74%)

17:31
05/18/18
05/18
17:31
05/18/18
17:31
Periodicals
Pinnacle Foods hires Evercore Partners to examine alternatives, NY Post says »

Pinnacle Foods (PF) has…

PF

Pinnacle Foods

$63.23

-0.45 (-0.71%)

CAG

Conagra Brands

$37.43

-0.28 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

MYND

MYnd Analytics

$3.28

0.075 (2.34%)

17:25
05/18/18
05/18
17:25
05/18/18
17:25
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INWK

InnerWorkings

$8.71

-0.08 (-0.91%)

17:16
05/18/18
05/18
17:16
05/18/18
17:16
Hot Stocks
InnerWorkings receives Nasdaq non-compliance letter due to late 10-Q filing »

InnerWorkings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

ADMA

ADMA Biologics

$5.46

0.05 (0.92%)

17:05
05/18/18
05/18
17:05
05/18/18
17:05
Syndicate
Breaking Syndicate news story on ADMA Biologics »

ADMA Biologics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMA

ADMA Biologics

$5.46

0.05 (0.92%)

17:05
05/18/18
05/18
17:05
05/18/18
17:05
Syndicate
Breaking Syndicate news story on ADMA Biologics »

ADMA Biologics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

17:04
05/18/18
05/18
17:04
05/18/18
17:04
Hot Stocks
Breaking Hot Stocks news story on Solid Biosciences »

Boxer Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDIT

Editas Medicine

$34.85

-3.14 (-8.27%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Editas Medicine data shows subretinal EDIT-101 injection tolerated in primates »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.57

-0.09 (-0.93%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Jamba announces expected receipt of Nasdaq letter »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLIC

Kulicke & Soffa

$21.98

-0.84 (-3.68%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Kulicke & Soffa receives Nasdaq notice of non-compliance »

Kulicke and Soffa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.